---
title: Serum Vitamin D Level and Its Association With Ovarian Reserve and IVF Outcome
nct_id: NCT02317718
overall_status: UNKNOWN
sponsor: Fakih IVF Fertility Center
study_type: OBSERVATIONAL
primary_condition: VITAMIN D Disorders
countries: United Arab Emirates
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT02317718.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT02317718"
ct_last_update_post_date: 2014-12-16
last_seen_at: "2026-05-12T06:53:16.785Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Serum Vitamin D Level and Its Association With Ovarian Reserve and IVF Outcome

**Official Title:** Serum Vitamin D Level in Subfertile Women and Its Association With Ovarian Reserve and IVF Outcome.

**NCT ID:** [NCT02317718](https://clinicaltrials.gov/study/NCT02317718)

## Key Facts

- **Status:** UNKNOWN
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 500
- **Lead Sponsor:** Fakih IVF Fertility Center
- **Conditions:** VITAMIN D Disorders
- **Start Date:** 2014-12
- **Completion Date:** 2015-07
- **CT.gov Last Update:** 2014-12-16

## Brief Summary

Vitamin D has a major play in bone and calcium metabolism. Vitamin D deficiency (below 20 ng/ml) has also been linked to adverse health outcomes such as malignancy, cardiovascular disease, immune functioning, and glucose metabolism. Recent data from retrospective and prospective trials have demonstrated contradictive results concerning the role of vitamin D in female reproduction and IVF outcome. Some studies have found that women deficient in vitamin D had lower ovarian reserve and significantly lower clinical pregnancy rates when compared to patients who were sufficient levels in vitamin D. Some studies also demonstrated that serum 25-OH-D3 levels correlates with antimullerian hormone (AMH) levels in women of advanced reproductive age. It may also have a role to play in endocrine dysfunction and abnormal folliculogenesis in polycystic ovaries .

The aim of this prospective cohort study including infertile women undergoing IVF treatment is to investigate the association between serum 25-OH- D3 levels and parametres of ovarian reserve (AMH, antral follicle count, number of oocytes collected) and clinical pregnancy and miscarriage rates .

## Detailed Description

Vitamin D has a major play in bone and calcium metabolism. Vitamin D deficiency (below 20 ng/ml) has also been linked to adverse health outcomes such as malignancy, cardiovascular disease, immune functioning, and glucose metabolism. Recent data from retrospective and prospective trials have demonstrated contradictive results concerning the role of vitamin D in female reproduction and IVF outcome. Some studies have found that women deficient in vitamin D had lower ovarian reserve and significantly lower clinical pregnancy rates when compared to patients who were sufficient levels in vitamin D. Some studies also demonstrated that serum 25-OH-D3 levels correlates with antimullerian hormone (AMH) levels in women of advanced reproductive age. It may also have a role to play in endocrine dysfunction and abnormal folliculogenesis in polycystic ovaries .

The aim of this prospective cohort study including infertile women undergoing IVF treatment is to investigate the association between serum 25-OH- D3 levels and parametres of ovarian reserve (AMH, antral follicle count, number of oocytes collected) and clinical pregnancy and miscarriage rates .

## Eligibility

- **Minimum age:** 20 Years
- **Maximum age:** 42 Years
- **Sex:** FEMALE
- **Healthy Volunteers:** Yes

```
Inclusion Criteria:

* Subfertile women,
* Indication for IVF,
* 20-42 yrs of age.

Exclusion Criteria:

* Women on therapeutic supplementation for Vitamin D Deficiency,
* Recurrent high order implantation failure
```

## Arms

- **Normal vitamin D levels group** — MORE THAN 20 NG/ML VITAMIN D LEVELS
- **Deficient Vitamin D GROUP** — LESS THAN 20 NG/ML LEVELS

## Interventions

- **monitor reproductive outcome** (OTHER)

## Primary Outcomes

- **Clinical pregnancy rate** _(time frame: 14 days post oocyte retrieval)_

## Secondary Outcomes

- **AMH (antimullerian hormone) Levels** _(time frame: day 2-3 of the index cycle)_
- **AFC (antral follicle count)** _(time frame: DAY 2-3 OF INDEX CYCLE)_
- **Number of oocytes retreived** _(time frame: Two weeks from the last menstrual period)_

## Locations (1)

- Fakihivf Fertiity Center, Abu Dhabi, Abu Dhabi Emirate, United Arab Emirates — _RECRUITING_

## Recent Field Changes (last 30 days)

- `results.hasResults` — added _(2026-05-12)_
- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `locations.fakihivf fertiity center|abu dhabi|abu dhabi emirate|united arab emirates` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT02317718.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT02317718*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*